Research Summary: R (GLP-3) is a triple GIP/GLP-1/glucagon receptor agonist (LY3437943). CAS 2381089-83-2. Single alpha-helical peptide with engineered multi-receptor selectivity; C20 fatty diacid for extended activity. Research peptide only.
Compound Specifications
GLP-3 is a triple incretin receptor agonist engaging GLP-1, GIP, and glucagon (GCGR) receptors simultaneously. CAS Registry Number: 2381089-83-2. Molecular weight: ~4,632.28 Da. Features a single alpha-helical peptide structure with engineered selectivity across all three receptor types. Research compound only.
Product Details
- Sizes: 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg
- Compound: GLP-3
- Classification: Triple incretin receptor agonist
- Purity: >99%
- Form: Lyophilized powder
- Testing: View COA (Verified by Janoshik) →
mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg
Research Studies
(for educational purposes only)
Triple Receptor Agonism: GLP-1/GIP/GCGR Mechanism
Source: PubMed PMID: 36070752
Summary: This study characterized GLP-3 as a single-molecule triple agonist in receptor binding and cell-based signaling assays, demonstrating simultaneous engagement of GLP-1R, GIPR, and glucagon receptor with distinct potency ratios. Preclinical work characterized concurrent engagement of all three receptor systems across receptor-binding and signaling assays.
Glucagon receptor signaling characterization
Source: PubMed PMID: 25365075
Summary: This review summarized glucagon receptor (GCGR) pharmacology and signaling characterization relevant to multi-receptor agonist research, including receptor-coupled assay systems and pathway profiling in preclinical models.
📚 View Published Research on GLP-3 →
Peer-reviewed citations from PubMed — for educational purposes only
